PP / MONOGRAPH 097 Dual GIP/GLP-1 receptor agonist peptide

Tirzepatide

Discovery history, preclinical evidence, human studies, current FDA context, and the questions that still need to be answered.

Evidence is not equivalence.

Research on a named molecule does not establish that a catalog material is the studied drug product. Identity, sequence, salt, formulation, purity, sterility, route, labeling, and indication can change the scientific and regulatory conclusion.

ORIGIN / HISTORY

When was Tirzepatide first described?

Tirzepatide was developed by Eli Lilly as a single peptide with dual GIP- and GLP-1-receptor agonism. Coskun and colleagues reported its preclinical and early clinical profile in 2018. [1]

PRECLINICAL EVIDENCE

What do animal and laboratory studies show?

Preclinical pharmacology may exist, but this registry does not treat animal or in-vitro findings as human outcomes. The literature map should be reviewed for the model, species, comparator, endpoint, and replication status. [2]

Translation limitCell and animal findings can generate mechanisms and safety signals, but they do not predict clinical benefit on their own.

CLINICAL EVIDENCE

Are there human studies?

FDA-approved tirzepatide products include Mounjaro and Zepbound, supported by SURPASS and SURMOUNT programs; exact indications and warnings are product- and label-specific. These findings apply only to the studied drug product, formulation, population, route, dose, and indication. [2][3]

Check the live study registry ↗

U.S. REGULATORY STATUS

Is Tirzepatide FDA cleared or approved?

Drug terminology: FDA generally approves drug products; “clearance” is typically a medical-device pathway.

One or more FDA-approved drug products use an active ingredient corresponding to Tirzepatide. FDA approval belongs to the specific application, manufacturer, formulation, strength, route, labeling, and indication—not to every material sharing the ingredient name. Confirm the exact product in Drugs@FDA. [4][5]

RESEARCH OUTLOOK

Where is the scientific promise?

The credible research opportunity for Tirzepatide is to define which findings reproduce across adequately powered trials, which endpoints are clinically meaningful, and how benefit–risk changes by indication and formulation. Existing human evidence cannot establish equivalence to an unverified catalog material. [2][3]

LIMITATIONS / PRECAUTIONS

What should professionals keep in view?

Same GI class effects; thyroid boxed warning; injection-site reactions; unverified gray-market potency. [2]

Professional-use boundary

This page does not provide a diagnosis, treatment recommendation, protocol, dose, reconstitution instruction, route, or administration schedule. Any lawful program requires independent regulatory, quality, toxicology, and clinical review.

SOURCE REGISTER

References and live evidence maps

Primary papers support specific historical claims where available. PubMed and ClinicalTrials.gov links are live evidence maps, not proof that every result applies to the exact catalog material. FDA links should be rechecked because regulatory pages and product labels can change.